Image via Wikipedia
AUGUSTA, Ga. – Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.
The study will include 40 children age 2-12 whose parents have stored cord blood at the Cord Blood Registry in Tucson, Ariz.
Umbilical cord blood is rich in stem cells, which can divide and morph into different types of cells throughout the body, said Dr. James Carroll, professor and chief of pediatric neurology in MCG School of Medicine and principal investigator
The Ospedali Riuniti of Bergamo is the top center for the collection of umbilical cord blood in the Lombardy region, said the hospital, which received an award at the Policlinico di Milano (where the umbilical cord blood bank is located) for the second consecutive year for its commitment and professionalism with which it carries out its work, providing an important source of stem cells.
“Our collection program started in 2004,” explained Bruna Pasini, the head obstetrician, also in charge of the collection of umbilical cord blood for the hospital. “At that time we started to collaborate with the Milano
Vanderbilt-Ingram Cancer Center performs around 215 stem cell and bone marrow transplants each year, providing care leading up
Stem Cell Therapy
Stem cell banking is gaining popularity in Indore and Bhopal as increasing numbers of parents are taking to the concept, which has the potential to secure their child’s healthy life.
The number of people who have registered for stem cell banking has increased multifold in Indore and Bhopal, placing them among the top 10 cities in the country, according to industry estimates.
Every month about 500 parents from Indore and Bhopal are investing in the potential life-saving power of stem cells by preserving the umbilical cord at child birth, whose stem cells help fight against any future life
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
The results of the StemEx study are expected during the second half of 2012
Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma,